This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
What is it? “Compound 25” is a selective, CNS-penetrant, ATP-competitive LRRK2 inhibitor that entered preclinical candidate enabling studies but was…
molecule
8 months ago ●
4 mins read
There were two novel small molecules approved in April 2022: mavacamten (Camzyos), an oral cardiac myosin inhibitor oteseconazole (Vivjoy), an…
Article
1 year ago ●
9 mins read
What is it? Compound 49 is an orally available CD73 inhibitor with dose-dependent PK/PD and an immune-mediated antitumor mechanism of…
molecule
8 months ago ●
3 mins read
Recently, Dr. Alf Claesson (CEO of Awametox AB, inventor of SpotRM, and previously Principal Scientist and Section Head at AstraZeneca/Astra…
Article
1 year ago ●
4 mins read
Toward a first-in-class DGAT2 inhibitor for the treatment of NASH. Hepatic triglyceride (TG) accumulation is a symptom of non-alcoholic fatty…
molecule
9 months ago ●
4 mins read
Momelotinib, an oral JAK1/2 inhibitor for myelofibrosis, is going to GSK as part of a $1.9 billion acquisition of Sierra…
Article
1 year ago ●
6 mins read
Load More
